Sirio Pharma acquisition of a majority stake of Best Formulations
We advised Sirio Pharma on the acquisition
Davis Polk advised Sirio Pharma Co., Ltd. in connection with its acquisition of a majority stake of Best Formulations. Sirio Pharma acquired Best Formulations as part of its strategy to meet the production needs of both international and local brands, as well as expanded capacity, global research and development collaboration, local market insights and diversification of products and services.
Sirio Pharma is a Chinese company that manufactures traditional and plant-based supplements in a wide range of dosage forms, including gummies, softgels, tablets, capsules, powders and beverages.
Best Formulations is a California company that specializes in plant-based softgels in the U.S., with new capabilities for nutritional gummies and personal care products.
The Davis Polk corporate team included partners Howard Zhang and Miranda So and associates Michael Zhuoran Xu and Luman Yu. The tax team included partner Kara L. Mungovan and associates Daniel L. Jose and William Liang. The executive compensation team included partner Veronica M. Wissel and associate Chloe Wang. The trust and estates team included associate Lucy McKinstry Taylor. Members of the Davis Polk team are based in the Beijing, Hong Kong, New York and Washington DC offices.